severe plaque psoriasis
Rheumatology · 2020–2025
2decisions
2medicines
2carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ustekinumab Severe chronic plaque psoriasis, severe psoriatic arthritis, severe Crohn disease, complex refractory fistulising Crohn disease, and moderate to severe… | Mar 2025 | Recommended with restriction | input received |
| tofacitinib Review of interchangeability advice for tofacitinib with other drugs for moderate-to-severe ulcerative colitis, severe psoriatic arthritis, severe rheumatoid… | Mar 2020 | Deferred | input received Colitis Australia |
Who spoke
Colitis Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.